A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats

July 1, 2012

Conclusion:  These results suggest that immunization with a novel vaccine is an effective means of inducing a morphine‐specific antibody response that is able to attenuate the behavioral and psychoactive effects of heroin. (Source: Journal of Neurochemistry)

Read the full article →

Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing

July 1, 2012

Abstract: Background: These studies compared the diversion and injection of buprenorphine-naloxone (BNX), buprenorphine (BPN) and methadone (MET) in Australia.Methods: Surveys were conducted with regular injecting drug users (IDUs) (2004–2009, N=881–943), opioid substitution treatment (OST) clients (2008, N=440) and authorised OST prescribers (2007, N=291). Key outcome measures include the unsanctioned removal of supervised doses, diversion, injection, […]

Read the full article →

Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients

July 1, 2012

Abstract: Background: This series of studies examines the pharmacokinetic/pharmacodynamic interactions between buprenorphine, an opioid partial agonist increasingly used in treatment of opioid dependence, and rifampin, a medication used as a first line treatment for tuberculosis; or rifabutin, an alternative antituberculosis medication.Methods: Opioid-dependent individuals on stable doses of buprenorphine/naloxone underwent two, 24-h blood sampling studies: (1) […]

Read the full article →

Gender differences in pharmacokinetics of maintenance dosed buprenorphine

July 1, 2012

Conclusions: Gender-related differences exist in the pharmacokinetics of buprenorphine; differences in body composition appear to have a major impact; differences in CYPA-dependent metabolism may also contribute. (Source: Drug and Alcohol Dependence)

Read the full article →

Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing

July 1, 2012

Source: Drug and Alcohol Dependence Area: Evidence > Medicines Management > References Background: These studies compared the diversion and injection of buprenorphine-naloxone (BNX), buprenorphine (BPN) and methadone (MET) in Australia. Methods: Surveys were conducted with regular injecting drug users (IDUs) (2004-09, N = 881 to 943), opioid substitution treatment (OST) clients (2008, N = 440) […]

Read the full article →

Lexapro Can Reduce Pain

July 1, 2012

Researchers at Boston University School of Medicine have found that opioid-dependent patients treated with Lexapro (escitalopram) had reduced pain severity and pain interference during the three months of their treatment. The study participants, who were beginning treatment with buprenorphine/naloxone for their opioid dependence, were placed in one of two groups:  escitalopram or placebo.  Changes in […]

Read the full article →

Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence: A 2-Phase Randomized Controlled Trial [Original Article]

July 1, 2012

Conclusions  Prescription opioid–dependent patients are most likely to reduce opioid use during buprenorphine-naloxone treatment; if tapered off buprenorphine-naloxone, even after 12 weeks of treatment, the likelihood of an unsuccessful outcome is high, even in patients receiving counseling in addition to SMM. Trial Registration  clinicaltrials.gov Identifier: NCT00316277 (Source: Archives of General Psychiatry) MedWorm Sponsor Message: Have […]

Read the full article →

Interactions Among Benzodiazepine and Buprenorphine/Naloxone

July 1, 2012

We read with interest the recent article by Heather Martin entitled “The Possible Consequences of Combining Lorazepam and Buprenorphine/Naloxone: A Case Review.” It is an interesting case study and we would like to express our thoughts on the drug interactions among benzodiazepine and buprenorphine/naloxone based on the literature review. (Source: Journal of Emergency Nursing: JEN)

Read the full article →

Suboxone is most effective in treating painkiller addiction

July 1, 2012

(McLean Hospital) Individuals addicted to prescription painkillers are more likely to succeed in treatment with the aid of the medication buprenorphine-naloxone (Suboxone), report McLean Hospital and Harvard Medical School researchers in today’s online edition of the Archives of General Psychiatry. (Source: EurekAlert! – Social and Behavioral Science)

Read the full article →

Painkiller abuse treated by sustained buprenorphine/naloxone

July 1, 2012

(NIH/National Institute on Drug Abuse) People addicted to prescription painkillers reduce their opioid abuse when given sustained treatment with the medication buprenorphine plus naloxone, according to research published in yesterday’s Archives of General Psychiatry and conducted by NIDA, part of the NIH. (Source: EurekAlert! – Social and Behavioral Science)

Read the full article →

← Previous Entries

Next Entries →